Talk Therapy for Insomnia May Slow Biological Aging in Older Adults

A good night’s sleep has long been treated as a comfort rather than a clinical priority, especially for older adults who are often told that sleeping poorly is simply part of growing older. A new randomized controlled clinical trial from UCLA Health challenges that assumption in a striking way. The study, published in The Lancet Healthy Longevity, found that when older adults with insomnia were treated with cognitive behavioral therapy, a structured, non-drug treatment that targets the thoughts and behaviors keeping people awake, they were not only far more likely to see their insomnia resolve, but also showed a measurably slower pace of biological aging compared with peers who received only sleep education. The finding positions insomnia not merely as a quality-of-life complaint, but as a potentially modifiable risk factor in the aging process itself.

The research team, led by Dr. Judith Carroll, associate professor of psychiatry at UCLA Health, set out to test whether treating a common sleep disorder could change something as fundamental as the speed at which the body ages. Insomnia is remarkably prevalent later in life: between 10 and 25 percent of adults over 65 in the United States are estimated to have clinical insomnia, a disorder characterized by persistent difficulty falling or staying asleep that impairs daytime functioning. Earlier observational studies had already linked insomnia to advanced biological aging, as measured by changes in DNA methylation, and to elevated risks of age-related diseases including cardiovascular disease, diabetes, and mortality. What remained unknown was whether the relationship was causal in a treatable direction, whether fixing the insomnia might actually slow the aging clock.

To address that question, the investigators conducted a randomized controlled trial in which nearly 100 older adults with insomnia were assigned to one of two interventions. The first was cognitive behavioral therapy for insomnia, often abbreviated CBT-I, which is considered the gold-standard, first-line treatment for the disorder. CBT-I is a structured, multi-session program delivered with a trained clinician, designed to identify and change the specific thoughts and behaviors that perpetuate sleeplessness, such as irregular sleep schedules, conditioned arousal in bed, and catastrophic beliefs about the consequences of a bad night. The second arm was sleep education therapy, an active control condition that provides general informational content about sleep and healthy sleep habits but omits the individualized behavioral techniques that define CBT-I. Comparing the two groups allowed the researchers to separate the specific effects of behavioral insomnia treatment from the benefits of simply learning more about sleep.

The biological readout of the trial came from blood. Samples were drawn before the eight-week treatment period began and again at follow-up visits over the following two years. From these samples, researchers extracted DNA and applied three widely used aging calculators, known as epigenetic clocks: DunedinPACE, GrimAge, and PC-PhenoAge. These tools rest on DNA methylation, a chemical modification in which small methyl groups are attached to specific positions in the genome, influencing whether genes are switched on or off. Methylation patterns shift in characteristic ways as people age, and statistical models trained on large datasets can translate a person’s methylation profile into an estimate of biological age or, as in this study, a pace of aging measured across time. Because the same participants were followed longitudinally, the clocks could capture changes within individuals rather than merely comparing different people.

The results were notable on two fronts. First, participants who underwent cognitive behavioral therapy had a nearly three-fold greater likelihood of achieving insomnia remission compared with those who received sleep education alone, reinforcing the established clinical superiority of CBT-I for older adults. Second, and more novel, insomnia treatment significantly slowed the pace of biological aging as measured by the DunedinPACE epigenetic clock, one of the three calculators tested. DunedinPACE is designed to quantify how fast a person is aging right now, rather than how old they appear, making it particularly sensitive to changes in the rate of biological decline over a study period. The fact that a behavioral intervention, delivered over just eight weeks, produced a detectable difference in this measure over two years of follow-up is the core of the study’s significance.

Dr. Carroll framed the implications in terms that reach well beyond sleep medicine. Insomnia in older adults, she noted, is often treated as a quality-of-life issue, but the findings suggest it may also be a modifiable risk factor for how the body ages. She drew an analogy to established preventive counseling: just as clinicians advise patients on physical activity and diet to support healthy aging, the study points to sleep as another important behavior worth targeting to improve long-term health. If replicated, that framing could elevate insomnia treatment from an optional comfort measure to a component of preventive care for aging populations, with potential downstream effects on the burden of cardiovascular disease, metabolic disease, and other conditions linked to accelerated biological aging.

The study’s authors are careful to spell out its limitations, and those caveats matter for how the findings should be interpreted. Participants were recruited from a single site in Los Angeles, California, which raises questions about generalizability. The authors state that a larger, multisite study with more diverse participants in terms of age, ethnicity, and race is needed to verify the results. They also note that more research is required to determine whether treatment response differs by sex, and whether other insomnia treatment options, such as medication or Tai Chi, could produce similar effects on the pace of aging. In other words, the trial establishes that CBT-I can slow an epigenetic measure of aging in this population, but it does not yet establish which patients benefit most, or whether alternative therapies confer the same biological advantage.

For readers wondering what DNA methylation has to do with sleep, the connection is part of a broader scientific effort to quantify aging at the molecular level. Epigenetic clocks like GrimAge and PC-PhenoAge were developed by training algorithms on methylation data from thousands of people, teaching them to predict chronological age or age-related health outcomes from chemical signatures scattered across the genome. DunedinPACE, developed using data from the long-running Dunedin birth cohort, estimates the pace of aging by tracking how quickly these signatures change. Studies have repeatedly shown that lifestyle factors, stress, and disease can shift these measures, and that faster pace scores predict earlier onset of chronic illness and mortality. The UCLA trial adds an important experimental element to this literature: rather than observing that insomniacs age faster, it tested whether treating the insomnia changes the trajectory, and found that it does, at least on one of the three clocks examined.

It is also worth emphasizing what the study does not claim. The researchers measured epigenetic aging over a two-year window; they did not report that treated participants lived longer or avoided disease, outcomes that would require much longer follow-up. The effect was observed on DunedinPACE but not highlighted for GrimAge or PC-PhenoAge, a pattern that underscores how sensitive these conclusions can be to the choice of clock. And as a secondary analysis from a randomized controlled trial, the aging findings, while compelling, are best viewed as hypothesis-generating until confirmed in larger and more diverse cohorts. The authors declared no competing interests, and the trial’s randomized design, longitudinal blood sampling, and use of validated epigenetic instruments give the result a methodological strength that much of the observational sleep-aging literature lacks.

Even with those qualifications, the message for the estimated millions of older adults living with untreated insomnia is concrete and actionable. An effective, widely available, medication-free treatment already exists, and the new evidence suggests its benefits may extend beyond better nights into the biology of aging itself. As the population over 65 grows, interventions that are inexpensive, scalable, and free of pharmacological side effects carry obvious public health appeal. The UCLA findings will now need to be tested at scale, but they add sleep to a short list of everyday behaviors, alongside diet and exercise, for which rigorous trial data suggest a direct link to the pace at which our bodies grow old.

Subject of Research: Cognitive behavioral therapy for insomnia and epigenetic measures of biological aging in older adults

Article Title: Cognitive behavioral therapy may reduce biological aging among older adults with insomnia

Article References: Cognitive behavioral therapy may reduce biological aging among older adults with insomnia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: insomnia, cognitive behavioral therapy, biological aging, epigenetic clocks, DNA methylation, older adults, DunedinPACE, sleep health, randomized controlled trial, The Lancet Healthy Longevity, UCLA Health, healthy longevity